The patterns of relapse in osteosarcoma: The Memorial Sloan-Kettering Experience
The patterns of relapse in osteosarcoma: The Memorial Sloan-Kettering Experience
复制标题
DOI：
10.1002/pbc.10420
复制
发表时间：
2004-01-01
影响因子：
3.2
通讯作者：
Gorlick, R
中科院分区：
文献类型：
--
作者：
Chi, SN;Conklin, LS;Gorlick, R
背景随着骨肉瘤强化大剂量化疗的引入，复发时观察到的转移模式发生了变化。为了进一步研究这一假设，我们分析了在纪念斯隆-凯特琳癌症中心接受不同强度化疗方案的各组的复发模式。Procedure.纳入了所有接受方案T4、T5、T7、T10和T12治疗的患者。患者被分为两组，一组包括接受强度较低治疗的患者（T4、T5和T7），另一组包括接受当前方案治疗的患者（T10和T12）。结果在25例早期复发的患者中，76%复发到肺部，8%局部复发，16%远处转移到骨。首次复发的中位时间为12个月。在T10和T12方案复发的69名患者中，75%在肺部复发，9%局部复发，16%远处骨转移。首次复发的中位时间为17个月。两组间的复发时间无统计学显著差异，尽管在后一种方案治疗的患者中观察到较长的复发中位时间。在后来的方案中，至复发的时间范围也更宽。结论.这些数据并不支持骨肉瘤复发模式随治疗改变而改变的假设。这种有限的单一机构经验可以在多机构努力的背景下进一步探讨。(c)2003 Wiley-Liss，Inc.
Background. With the introduction of intensive high-dose chemotherapy for the treatment of osteosarcoma, changes in the pattern of metastases observed at relapse have been reported. To further investigate this hypothesis, the relapse patterns among groups receiving chemotherapy regimens of variable intensity at Memorial Sloan-Kettering Cancer Center were analyzed. Procedure. All patients treated with the protocols T4, T5, T7, T10, and T12 were included. Patients were divided into two groups, one including those patients treated with less intense therapy (T4, T5, and T7) and the other, those treated with current regimens (T10 and T12). Results. Of the 25 patients who relapsed on the earlier protocols, 76% relapsed to the lungs, 8% had local recurrences, and 16% distant metastases to the bone. The median time to first relapse was 12 months. Of the 69 patients who relapsed on the T10 and T12 protocols, 75% relapsed in the lungs, 9% had local recurrences, and 16% distant bone metastases. The median time to first relapse was 17 months. There was no statistically significant difference in the timing of relapse between the two groups studied, although a longer median time to relapse was observed for patients treated on the later protocols. The range of time to relapse was also wider in the later protocols. Conclusions. These data do not support the hypothesis that patterns of relapse are changing with alterations in osteosarcoma treatment. This limited single institutional experience can be explored further in the context of a multi-institutional effort. (c) 2003 Wiley-Liss, Inc.